Latest court orders, judgments, and legal developments from Indian courts — AI-curated and summarized.
In the case of Novartis AG v. Venkata Narayana Active Ingredients, the Madras High Court examined the evidentiary requirements for invoking Section 107A related to Bolar exemptions. The decision aims to simplify compliance for manufacturers seeking regulatory approval for exports.
The CDSCO's notice regarding the scrutiny of brand name extensions used by pharma companies signals a shift towards regulatory oversight in the pharmaceutical sector. This inquiry may impact how brand identities are managed in compliance with drug regulations.
Recent developments involving the Serum Institute of India regarding a Nipah vaccine and the sidelining of an indigenous HPV vaccine highlight ongoing issues in India's vaccine policy. These cases underscore significant challenges related to transparency and access.
In a two-part exploration, the challenges of access to patented medicines in India are discussed, focusing on legislative mechanisms that have become dormant.
A new book titled 'Fractures in IP, Trade, and Health' co-authored by Prof Srividhya Ragavan explores the intersection of public health and intellectual property. The book discusses pressing issues in the context of global trade.
Prof. Srividhya Ragavan and co-author publish 'Fractures in IP, Trade, and Health', focusing on public health frameworks. The book discusses critical intersections of IP and trade in relation to health.
The CDSCO invites comments on the use of brand name extensions by pharmaceutical companies amidst concerns of misleading practices.
The CDSCO seeks feedback regarding the use of brand name extensions in pharmaceuticals, prompting a long-overdue examination of practices that potentially mislead consumers. Experts highlight the implications for compliance and regulatory oversight.
The Directorate General of Health Services has opened a public consultation on the issue of brand name extensions used by pharmaceutical companies, a practice that may compromise patient safety. This could lead to stricter regulations in the industry.